Dr. Manuela Stauss-Grabo
Fresenius Medical Care Deutschland GmbH
Fresenius Medical Care is an integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure as well as immune apheresis and other therapy fields. As a market-leading company, Fresenius Medical Care continually endeavors to further increase therapy and product quality in the interests of optimal patient care. Therefore, Fresenius Medical Care supports the Target-to-B! Consortium with focus on WP 8: “Effects and clinical efficacy of antibody removal in B-IMD (immune-mediated disease)/B-ONC (oncology)”. With the support of WP8 Fresenius Medical Care intends to support to gain more knowledge on the response to immune-depleting therapies and to further optimize immune apheresis therapy in patients suffering from B-cell related autoimmune diseases and paraprotein associated diseases.
Member of workpackage 8.